Global Competition Review has ranked Goodwin as a top global firm in the 2026 edition of GCR 100. GCR 100 conducts in-depth research evaluating the size, activity, and reputation of antitrust practices in order to offer a comprehensive listing of the world’s best competition law firms.
The guide recognized the leadership of Antitrust & Competition practice co-chairs Andrew Lacy and Arman Oruc, as well as partner Sarah Jordan in the United Kingdom. It also highlighted the addition of partners Stephen Mavroghenis in the firm’s new Brussels office and Alexandra Russell in Washington, DC.
Goodwin received recognition for its Antitrust & Competition practice in Massachusetts, Washington, DC, and the United Kingdom.
GCR 100 highlighted Goodwin’s representation of 47 Brand in its acquisition by New Era Cap, and also cited the firm advising Endomagnetics in its sale to Hologic, Blueprint Medicines on its $9.5 billion acquisition by Sanofi, and SpringWorks Therapeutics in its $3.9 billion merger with Merck. Additionally, GCR recognized Goodwin’s representation of Teva Pharmaceuticals, BNP Paribas, and Rainmaker Group in critical antitrust litigation.
Goodwin’s Antitrust & Competition practice has exceptional experience advising clients ranging from the largest Fortune 500 companies to emerging growth companies on transactions and investigations before US, EU, UK, and worldwide antitrust agencies. The practice stands out for its significant, high-profile work in the life sciences, technology and private equity industries including merger clearance work, dominance and cartel investigations, and bet-the-company litigation.
To learn more about Goodwin’s rankings, visit GCR 100 2026.